/
CNTX
$0.51+$0.04 (+7.77%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$43.2M
92M shares
52-week range
$0.43 – $3.62
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-4.59
Context Therapeutics Inc. Common Stock
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
www.contexttherapeutics.com- Employees
- 15
- IPO / List date
- Oct 20, 2021
- HQ
- PHILADELPHIA, PA
Held by traders on TradeandTell
No one on the platform currently holds CNTX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 182,999 | $479.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CNTX yet.
